Compare VRE & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRE | ARDX |
|---|---|---|
| Founded | 1949 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | 1995 | 2014 |
| Metric | VRE | ARDX |
|---|---|---|
| Price | $18.94 | $5.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $19.50 | $15.14 |
| AVG Volume (30 Days) | 1.2M | ★ 3.0M |
| Earning Date | 04-22-2026 | 04-30-2026 |
| Dividend Yield | ★ 1.69% | N/A |
| EPS Growth | ★ 420.00 | N/A |
| EPS | ★ 0.80 | N/A |
| Revenue | ★ $288,434,000.00 | $2,607,000.00 |
| Revenue This Year | N/A | $37.75 |
| Revenue Next Year | $2.87 | $34.24 |
| P/E Ratio | $23.69 | ★ N/A |
| Revenue Growth | ★ 6.40 | N/A |
| 52 Week Low | $13.69 | $3.50 |
| 52 Week High | $18.97 | $8.40 |
| Indicator | VRE | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 73.85 | 49.73 |
| Support Level | $18.83 | $5.49 |
| Resistance Level | $18.97 | $6.23 |
| Average True Range (ATR) | 0.05 | 0.25 |
| MACD | -0.10 | 0.09 |
| Stochastic Oscillator | 85.72 | 76.73 |
Veris Residential Inc is a fully-integrated, self-administered and self-managed real estate investment trust (REIT). The company owns and operates a real estate portfolio comprised predominantly of multifamily rental properties located mainly in the Northeast and Class A office properties. The company performs substantially all real estate management, leasing, acquisition and development on an in-house basis. The properties are in three states in the Northeast, plus the District of Columbia. The company operates in two industry segments multifamily real estate & services and commercial & other real estate. The majority of revenue is from Multifamily real estate services.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.